GUANGZHOU, China, November 11, 2026 / PRNewswire / -- POMDOCTOR LIMITED ("Pomdoctor" or "the Company") (Nasdaq ticker: POM) is a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions. The company emphasized today the strategic importance of its real-world data ("RWD") assets in transforming healthcare services and decision-making, and introduced the capabilities that the company is building to serve as a foundation for advancing predictive and data-driven healthcare solutions.

As medical systems increasingly adopt digital technologies, RWD is evolving from a supplementary source of information to an important resource for evidence-based medical decision-making. RWD aims to provide multi-dimensional and valuable insights into patient conditions, treatment responses, and long-term health outcomes by collecting continuous health data from clinical practices, wearable devices, medication records, and daily activities. If these data can be systematically collected, integrated, and analyzed, it will help to bridge the gap between clinical research and real-world medical practice, thereby supporting more informed medical decisions and better medical management.

The application of RWD in the medical ecosystem is continuously expanding.

RWD is playing an increasingly important role in the healthcare ecosystem, creating opportunities for improving medical research, clinical practice, and the allocation of healthcare resources.

In terms of pharmaceutical research and development, real-world studies based on RWD ("RWS") can complement clinical trials by providing additional insights into treatment effectiveness, medication adherence, and long-term patient outcomes. Such evidence helps pharmaceutical companies better understand how treatment regimens perform in routine clinical settings and provides a reference for drug development and commercialization strategies.

In clinical practice, RWD can support evidence-based guidelines and help doctors make more informed treatment decisions based on a broader range of patient information and observed treatment outcomes.

In the medical payment system, RWD helps to evaluate treatment outcomes, cost-effectiveness, and medical usage, thereby supporting more comprehensive reimbursement and risk management strategies.

In addition, when the analysis driven by RWD and AI is combined, continuous patient data can help identify risks earlier, develop personalized treatment plans, and manage chronic diseases more proactively. The company expects that these capabilities will play an increasingly important role in the transition of medical models from passive treatment to preventive, predictive, and personalized healthcare.

Pomdoctor's Data-Driven Healthcare Strategy

Building on existing medical platforms and doctor networks, Pomdoctor is advancing an integrated RWD ecosystem that encompasses physiological indicators, behavior patterns, medication records, remote patient monitoring (“RPM”) data, as well as information related to medical payments.

By integrating wearable technology, AI analysis, and doctor-led interventions, the company aims to establish a continuous medical data feedback loop that connects health monitoring, risk assessment, personalized interventions, and long-term patient management. This integrated approach is designed to transform fragmented medical information into structured, actionable insights to support individual patient care and a broader range of medical applications.

Pomdoctor believes that high-quality, multi-dimensional medical data is one of its key competitive advantages in the era of digital healthcare. The company stated that it will enhance AI capabilities through continuous accumulation and analysis of real-world medical information, improve clinical decision support, and promote the commercialization of RWD applications, including pharmaceutical research collaboration and enterprise medical data services.

Pomdoctor Chairman and CEO Shenyang Shi ( Zhenyang Shi ) stated: "We believe that RWD is increasingly becoming an important cornerstone of the next generation of healthcare services. In Pomdoctor, we are integrating AI, wearable technology, and medical data to transform fragmented medical information into actionable insights, thereby supporting more comprehensive and personalized medical decisions. We are confident that our continuously expanding data capabilities will support more personalized, predictive, and efficient healthcare services, and create meaningful long-term value throughout the entire healthcare ecosystem."

About POMDOCTOR LIMITED

POMDOCTOR LIMITED (Nasdaq ticker: POM) is a Chinese digital healthcare company that operates an internet hospital platform for chronic diseases and a pharmaceutical supply chain business. Historically, these two businesses generated revenue mainly through drug sales and related medical services. The company is currently focused on advancing AI enabled healthcare solutions and expanding predictive healthcare capabilities. It aims to leverage doctor resources, wearable technology, artificial intelligence, healthcare payment networks, and real-world medical data to support more personalized, sustainable, and data-driven medical services. Building on its existing healthcare platforms and doctor network, POM is advancing the construction of predictive healthcare data and service infrastructure, with the goal of improving medical outcomes and creating long-term value for patients, healthcare providers, and other ecosystem participants. For more information, please visit the company's website: http :// ir.7shiliu.com.

Forward-looking Statements

This announcement contains forward-looking statements as defined under Section 27A of the Securities Act of 1933 (as amended), Section 21E of the Securities Exchange Act of 1934 (as amended), and the Private Securities Litigation Reform Act of 1995 of the United States. These statements are made under the ‘safe harbor’ provisions of such acts. Except for historical facts, all statements are forward-looking and include, but are not limited to: the company’s strategic evolution from a traffic-based monetization model to a value-based healthcare payment and monetization model; the company’s plans to further strengthen its four-tier revenue structure covering B2C essential healthcare services, AI empowered chronic disease member subscriptions, B2B enterprise and hospital services, as well as pharmaceutical RWS / RWD services, and to integrate these businesses into a more comprehensive healthcare ecosystem; the company’s development and piloting of AI empowered healthcare projects, and its ability to transform clinical applications into scalable, revenue-generating services; the company’s plans to integrate AI technology, wearable devices, and existing digital healthcare infrastructure, and its belief that such integration can gradually convert data assets into a source of incremental commercial value; the company’s expectations for growth in recurring subscription revenue, expansion of institutional coverage, and enhancement of relationships with healthcare providers (including public hospitals) and pharmaceutical companies, as well as the development of higher-value pharmaceutical RWS / RWD services; the company’s belief that its interconnected business model is designed to balance short-term revenue and cash flow with long-term growth opportunities and to create a potential flywheel effect; the company’s exploration of opportunities to replicate and adjust its business model in major international markets; and the expected benefits of the company’s strategy for patients, healthcare providers, pharmaceutical companies, shareholders, and other ecosystem participants, including sustainable long-term value creation.Investors can identify many (but not all) of these forward-looking statements through phrases such as "expected," "believes," "hopes," "anticipates," "intends," "estimates," "project," "plans," "seeks," "positions," "will," "shall," "should," "may," and similar expressions. These forward-looking statements are based on the company's current expectations, assumptions, and projections regarding future events, which the company believes may affect its financial condition, operating results, business strategy, and capital needs. They involve known and unknown risks and uncertainties beyond the company's control. Although the company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee that they will be realized. Investors are advised not to rely excessively on these forward-looking statements. All forward-looking statements are as of the date of this announcement, and the company assumes no obligation to publicly update or revise any such statements unless required by law.

Due to various factors and uncertainties, the actual results may differ significantly from those explicitly or implicitly stated in the forward-looking statements. These include, but are not limited to: the risk that the company's initiatives in enabling healthcare (including its Chronic Disease Management System, analytics capabilities, and other related technologies) may not be developed, validated, deployed, or commercialized on schedule, or may not succeed at all; the ongoing changes in laws and regulations regarding healthcare technology, internet-based healthcare services, medical devices, personal information protection, data security, and cross-border data transmission in China and other regions, which may impose restrictions on the company's ability to collect, use, de-identify, or commercialize relevant data; cybersecurity incidents and data breaches; as well as competition from other companies with similar technologies and data resources. Investors are advised to refer to the "Item 3. Key Information – D. Risk Factors" section of the company's 20-F annual report for the fiscal year ending December 31, 2025, submitted to the U.S. Securities and Exchange Commission (SEC) on May 14, 2026, as well as other documents submitted by the company to the SEC. These documents can be found on the company's official website.

For more information, please contact:

POMDOCTOR LIMITED

Ascent Investor Relations LLC